Institutional members access full text with Ovid®

Combination Lipid-Lowering Drugs and Cancer Risk

Aschenbrenner, Diane S. MS, APRN-BC

AJN, American Journal of Nursing: May 2010 - Volume 110 - Issue 5 - p 24
doi: 10.1097/01.NAJ.0000372065.11566.53
Drug Watch

* There is no evidence that the combination cholesterol-lowering drug Vytorin (simvastatin plus ezetimibe) increases the risk of cancer or cancer-related death.

* Patients taking Vytorin should continue to do so.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2010 Lippincott Williams & Wilkins, Inc.